2. Search Result
Search Result
Results for "

D1R

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

1

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-178103
    D1R antagonist 2

    		Dopamine Receptor Arrestin Neurological Disease
    D1R antagonist 2 (Compound 13a) is a BBB-penetrable D1R antagonist with IC50s of 35.6 and 70 nM for cAMP-based D1R and β-arrestin-based D1R, respectively. D1R antagonist 2 effectively antagonizes D1R-mediated cAMP and β-arrestin recruitment. D1R antagonist 2 can be used for neurodegenerative and neuropsychiatric diseases such as schizophrenia, Parkinson’s disease and Alzheimer’s disease research [1].
    D1R antagonist 2
  • HY-123837
    MLS1082

    		Dopamine Receptor Neurological Disease
    MLS1082 is a pyrimidone-based D1-like dopamine receptor positive allosteric modulator, with an EC50 of 123 nM for DA-stimulated G protein signaling [1].
    MLS1082
  • HY-149336
    D1R antagonist 1

    		Dopamine Receptor Neurological Disease
    D1R antagonist 1 (compound 12a) is a D1R antagonist, involved in G-protein- and β-arrestin-based signaling [1].
    D1R antagonist 1
  • HY-141495
    (Rac)-Razpipadon
    1 Publications Verification

    PW0464

    		 Dopamine Receptor Neurological Disease
    PW0464, a nanomolar potent complete G protein biased ligand, is a noncatechol D1R agonist, with an EC50 of 5.8 nM (Gs-cAMP) [1].
    (Rac)-Razpipadon
  • HY-175504
    MLS6357

    		Dopamine Receptor PERK Neurological Disease
    MLS6357 is a D3 dopamine receptor (D3R)-selective positive allosteric modulator (PAM)-antagonist. MLS6357 exhibits antagonist activity in the D3R-mediated and the BRET-based β-arrestin recruitment assay with IC50s of 13 and 14 μM, and no activity for other DAR subtypes (D1R/D2R/D4R/D5R) (IC50 > 100 μM). MLS6357 is also an antagonist in the D3R-mediated Go-BRET assay with an IC50 of 17 μM. MLS6357 can be used for the study of neuropsychiatric disorders, including substance use disorder [1].
    MLS6357
  • HY-179241
    UNC10062

    		Dopamine Receptor Neurological Disease
    UNC10062 is a dopamine D1 receptor (D1R) positive allosteric modulator. UNC10062 specifically binds to the extracellular allosteric pocket (upper pocket) at the interface of transmembrane helices (TM) 1 and 7 of D1R. UNC10062 can increase dopamine potency and D1R-mediated cAMP production. UNC10062 can be used for the research of neurological disease, such as Parkinson's disease [1].
    UNC10062
  • HY-129089
    (-)-MDO-NPA

    		Dopamine Receptor Neurological Disease
    (-)-MDO-NPA is an N-propylnorapomorphine analog and a D1R/D2R dual-target ligand. (-)-MDO-NPA has EC50 values of 1949 nM (D1R) and 520 nM (D2R) for β-arrestin. (-)-MDO-NPA has EC50 values of 717.5 nM (D1R) and 7.7 nM (D2R) for cAMP. (-)-MDO-NPA can be used in the research of dopamine-related diseases such as Parkinson’s disease [1].
    (-)-MDO-NPA
  • HY-175001
    D1/D5 Receptor agonist-1

    		Dopamine Receptor Arrestin Neurological Disease
    D1/D5 Receptor agonist-1 is a highly brain-penetrant and orally active D1/D5 receptor agonist. D1/D5 Receptor agonist-1 maintains considerable efficacy in the cAMP pathway and in β-arrestin recruitment, with EC50s of 3.7 nM (D1R cAMP), 91 nM (D1R β-arrestin), 129 nM (D1R internalization) and a Ki of 111 nM (D1R binding affinity). D1/D5 Receptor agonist-1 inhibits β-arrestin signaling in a rat with L-DOPA (HY-N0304) induced dyskinesias. D1/D5 Receptor agonist-1 can be used for the study of Parkinson’s disease [1].
    D1/D5 Receptor agonist-1
  • HY-179240
    UNC9815

    		Dopamine Receptor Neurological Disease
    UNC9815 is a D1 dopamine receptor (D1R) orthosteric allosteric modulator (PAM). UNC9815 can dose-dependently enhance the functional efficacy of dopamine in β-inhibitory protein recruitment experiments and cAMP accumulation experiments. When used in combination with other PAMs, UNC9815 exhibits a significant synergistic enhancement effect. UNC9815 can be used to study neurological and psychiatric diseases such as Parkinson's disease and schizophrenia [1].
    UNC9815
  • HY-W664041
    Noncatechol agonist-1

    		Dopamine Receptor Neurological Disease
    Noncatechol agonist-1 (19) is a Noncatechol agonist with full efficacy at both D1R-G protein and D1R-β-arrestin2 pathways, with pEC50 values of 8.41 for D1R-mediated cAMP production and 7.7 for β-arrestin2 recruitment, respectively [1].
    Noncatechol agonist-1
  • HY-175532
    M4 mAChR Modulator-2

    		mAChR Neurological Disease
    M4 mAChR Modulator-2 is an orally active, selective, brain-penetrant positive allosteric modulator (PAM) of the M4 muscarinic acetylcholine receptor (M4 mAChR) (EC50 = 513 nM). M4 mAChR Modulator-2 exhibits high target selectivity, showing negligible affinity and low inhibition rates for non-target receptors (D1R/D2R/D3R, 5-HT subtypes, κ/δ/μ opioid receptors, H1, M1/M2) while specifically binding to M4 mAChR with a Ki of 377 nM and an inhibition rate of 62.8%. M4 mAChR Modulator-2 reverses Dizocilpine (MK-801) (HY-15084B)-induced hyperlocomotion in mice. M4 mAChR Modulator-2 can be used for the study of schizophrenia [1]
    M4 mAChR Modulator-2
  • HY-13631K
    (1R,9S)-Dxd

    		ADC Payload Cancer
    (1R,9S)-Dxd is an isomer of (Dxd) HY-13631D. (1R,9S)-Dxd is an ADC payload that can be used in the synthesis of ADCs (antibody-drug conjugates) [1].
    (1R,9S)-Dxd
  • HY-RS03994
    DRD1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    DRD1 Human Pre-designed siRNA Set A contains three designed siRNAs for DRD1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    DRD1 Human Pre-designed siRNA Set A
    DRD1 Human Pre-designed siRNA Set A
  • HY-13956A
    (R)-Pioglitazone-d1

    (R)-U 72107-d1

    		 Endogenous Metabolite Inflammation/Immunology
    (R)-Pioglitazone-d1 ((R)-U 72107-d1) is a stabilized and deuterated R-enantiomer of pioglitazone, exhibiting pharmacological properties that are beneficial for NASH treatment, including modulation of mitochondrial function, non-steroidal anti-inflammatory effects, and glucose-lowering capabilities.
    (R)-Pioglitazone-d1
  • HY-183776
    Dopamine D3 receptor agonist-2

    		Dopamine Receptor Others
    Dopamine D3 receptor agonist-2 is a selective dopamine D3 receptor partial agonist with a Ki of 0.268 nM. Dopamine D3 receptor agonist-2 exhibits 29-fold selectivity over dopamine D2 receptor (Ki= 7.67nM) [1].
    Dopamine D3 receptor agonist-2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: